Biotricity (BTCY) Stock Overview
A medical technology company, provides biometric data monitoring solutions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
BTCY Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Biotricity, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.29 |
| 52 Week High | US$0.83 |
| 52 Week Low | US$0.23 |
| Beta | 1.41 |
| 1 Month Change | -12.50% |
| 3 Month Change | -50.56% |
| 1 Year Change | -5.50% |
| 3 Year Change | -94.55% |
| 5 Year Change | -95.96% |
| Change since IPO | -98.18% |
Recent News & Updates
Recent updates
Investors Give Biotricity, Inc. (NASDAQ:BTCY) Shares A 38% Hiding
Jan 26
Many Still Looking Away From Biotricity, Inc. (NASDAQ:BTCY)
Oct 26Biotricity GAAP EPS of -$0.09, revenue of $2.06M
Aug 15Biotricity, Inc.: A First Take
Jul 28Is Biotricity (NASDAQ:BTCY) Using Debt In A Risky Way?
Apr 09Does Biotricity (NASDAQ:BTCY) Have A Healthy Balance Sheet?
Dec 11Biotricity: Capital Raise Leads To Buying Opportunity
Aug 31Shareholder Returns
| BTCY | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -3.8% | 0.9% | -0.3% |
| 1Y | -5.5% | -14.1% | 13.0% |
Return vs Industry: BTCY exceeded the US Healthcare Services industry which returned -17.4% over the past year.
Return vs Market: BTCY underperformed the US Market which returned 12.5% over the past year.
Price Volatility
| BTCY volatility | |
|---|---|
| BTCY Average Weekly Movement | 15.8% |
| Healthcare Services Industry Average Movement | 8.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BTCY's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BTCY's weekly volatility has decreased from 21% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 46 | Waqaas Al-Siddiq | www.biotricity.com |
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux and Biocore Pro, an integrated ECG device and software that utilizes wet electrodes for cardiac outpatient monitoring (COM) market; Biocore, a Holter and Extended Holter monitors for cardiac diagnostics; Biocare which support medical practitioners to gather data, and regularly monitor and treat patients with two or more chronic care conditions; Bioheart that offers preventative care and disease management solutions; and Biokit, a remote patient monitoring kit for cardiac patients that had other chronic conditions such as hypertension or COPD.
Biotricity, Inc. Fundamentals Summary
| BTCY fundamental statistics | |
|---|---|
| Market cap | US$7.83m |
| Earnings (TTM) | -US$4.87m |
| Revenue (TTM) | US$15.08m |
Is BTCY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BTCY income statement (TTM) | |
|---|---|
| Revenue | US$15.08m |
| Cost of Revenue | US$3.04m |
| Gross Profit | US$12.04m |
| Other Expenses | US$16.91m |
| Earnings | -US$4.87m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 79.84% |
| Net Profit Margin | -32.27% |
| Debt/Equity Ratio | -84.8% |
How did BTCY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/22 12:19 |
| End of Day Share Price | 2026/01/22 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biotricity, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin Dede | H.C. Wainwright & Co. |
| Jason Wittes | Northland Capital Markets |